There\u2019s a silent but radical shift reshaping the value of medical devices, more than any new technology or algorithm.<\/p>
A shift born in real life: in patients\u2019 routines, phones, homes, and clinical journeys.<\/p>
Its name is Real-World Evidence (RWE)<\/strong>. A device is no longer something you place on the market. It is a living system<\/strong>: generating data continuously, constantly evolving , and requiring continuous stewardship.<\/p> 2026 won\u2019t be the year of new<\/em> devices. For years, post-market meant vigilance forms, PMS plans, periodic reports. Today, devices live across ecosystems: wearables, apps, EMRs, sensors, registries. Under MDR, the European Commission leaves no ambiguity: post-market surveillance is central<\/strong> to continuous risk and performance evaluation.<\/p> Real-World Data captures health information outside randomised trials. For medical devices (especially digital and AI-enabled) RWE makes it possible to:<\/p> Trials show what can<\/em> happen. Three forces have aligned across 2025\u20132026:<\/p> The traditional post-market framework can\u2019t keep up. Not a linear cycle (\u201cdevelop \u2192 approve \u2192 monitor\u201d), but a continuous evidence ecosystem<\/strong> where a device:<\/p> In practical terms: a device never stops. And it never stops talking.<\/strong><\/p> Post-Market 2.0 demands:<\/p>
And it is turning post-market from a formal requirement into a strategic engine of safety, performance, competitiveness, and trust<\/strong>.<\/p>
It will be the year of devices that can prove<\/strong> they work beyond controlled environments.<\/p>The old post-market model has reached its limit<\/strong><\/h2>
A downstream, administrative workflow built for a world where devices were stable, software was static, and data was scarce. That world is gone.<\/p>
Every interaction creates a real-world signal, a micro-evidence unit.
Systems that generate hundreds of thousands of data points a month cannot be monitored with tools designed for quarterly reports.<\/p>From RWD to RWE: turning data into real clinical proof<\/strong><\/h2>
When analysed with rigour, it becomes Real-World Evidence<\/strong>: insight generated by life, not by protocol.<\/p>
RWE shows what does<\/em> happen.<\/p>Why this shift is happening now<\/strong><\/h2>
This is where Post-Market 2.0<\/strong> emerges.<\/p>What Post-Market 2.0 really means<\/strong><\/h2>